Integra Buys IsoTis, Gains Accell Demineralized Bone Matrix In $51 Mil. Deal
This article was originally published in The Gray Sheet
Executive Summary
Closure of Integra LifeSciences' acquisition of orthobiologics firm IsoTis is conditioned upon 510(k) clearance for IsoTis' Accell line of demineralized bone matrix products, Integra says
You may also be interested in...
Integra Issues Delayed 2007 Results, Reports Orthobiologics Integration
Integra Lifesciences is lagging behind in reporting its financial results, but in the meantime has put in place an expanded orthobiologics business
Integra Issues Delayed 2007 Results, Reports Orthobiologics Integration
Integra Lifesciences is lagging behind in reporting its financial results, but in the meantime has put in place an expanded orthobiologics business
IsoTis Accell gains FDA clearance
Integra LifeSciences' pending acquisition of orthobiologics firm IsoTis moves a step closer to completion with the Aug. 15 receipt of 510(k) clearance for IsoTis' Accell line of demineralized bone matrix products. Accell is a key asset of the $51 million deal, which was announced Aug. 7 and conditioned upon Accell market go-ahead. The Accell products are indicated for use as bone graft extenders in the spine, extremities and pelvis, or as bone void fillers in the extremities and pelvis (1"The Gray Sheet" Aug. 13, 2007, p. 10)...